Form 4: Orchestra BioMed CEO David Hochman Reports Routine Stock Withholding for Tax Obligations

Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman reported a routine transaction involving the withholding of shares to cover tax obligations related to the vesting of restricted stock units.

Summary

• David P. Hochman, the Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), filed a Form 4 with the SEC.
• The filing details a transaction on June 11, 2025, where shares of Common Stock were withheld by the Issuer to satisfy tax withholding obligations.
• A total of 34,038 shares were withheld from direct ownership and 5,671 shares from indirect ownership (via the DPH 2008 Trust) at a price of $3.14 per share.
• The filing explicitly states that no shares were sold in the market as a result of this vesting and tax satisfaction.
• Following these transactions, Mr. Hochman beneficially owns 545,460 shares directly and 338,471 shares indirectly through various trusts (DPH 2008 Trust, Solomon Ascher Hochman 2019 Trust, Hannah Hochman 2019 Trust, Judah Herman Hochman 2019 Trust, and NSH 2008 Family Trust).

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine compliance filing detailing a non-discretionary transaction (tax withholding) related to equity compensation, not a sale or purchase indicating a change in sentiment towards the company's prospects.

Future Outlook

This document is a compliance filing (Form 4) and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a tax withholding event, and does not provide broader industry context or trends. Such transactions are common across all industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and not a market sale by an insider.
• Employees: No direct impact beyond the reporting person, but it reflects standard equity compensation practices.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, David P. Hochman, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Tax Withholding